Reactive bone marrow stromal cells attenuate systemic inflammation via sTNFR1

Molecular Therapy

Volumn 18, Issue 10, 2010, Pages 1857-1864

  Yagi, Hiroshi ^a,b   Soto Gutierrez, Alejandro ^a,c   Navarro Alvarez, Nalu ^a   Nahmias, Yaakov ^a,d   Goldwasser, Yoni ^a   Kitagawa, Yuko ^b   Tilles, Arno W ^a   Tompkins, Ronald G ^a   Parekkadan, Biju ^a   Yarmush, Martin L ^a,e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b KEIO UNIVERSITY   (Japan)

^c CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^d HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^e RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVITY; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFLAMMATION; KIDNEY; LIVER; LUNG; MACROPHAGE MIGRATION; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; RAT;

ANIMALIA; RATTUS;

EID: 77957580211     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.155     Document Type: Article

References (50)

1. Heron, M, Hoyert, DL, Murphy, SL, Xu, J, Kochanek, KD and Tejada-Vera, B (2009). Deaths: final data for 2006. Natl Vital Stat Rep 57: 1-134.
2. Robertson, CM and Coopersmith, CM (2006). The systemic inflammatory response syndrome. Microbes Infect 8: 1382-1389.
3. Heidecke, CD, Hensler, T, Weighardt, H, Zantl, N, Wagner, H, Siewert, JR et al. (1999). Selective defects of T lymphocyte function in patients with lethal intraabdominal infection. Am J Surg 178: 288-292.
4. Tracey, KJ, Fong, Y, Hesse, DG, Manogue, KR, Lee, AT, Kuo, GC et al. (1987). Anti?cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330: 662-664.
5. Deans, KJ, Haley, M, Natanson, C, Eichacker, PQ and Minneci, PC (2005). Novel therapies for sepsis: a review. J Trauma 58: 867-874.
6. Ulloa, L and Tracey, KJ (2005). The "cytokine profile": a code for sepsis. Trends Mol Med 11: 56-63.
7. Lakshmanan, U and Porter, AG (2007). Caspase-4 interacts with TNF receptorassociated factor 6 and mediates lipopolysaccharide-induced NF-kappaB-dependent production of IL-8 and CC chemokine ligand 4 (macrophage-inflammatory protein-1). J Immunol 179: 8480-8490.
8. Anderson, P (2008). Post-transcriptional control of cytokine production. Nat Immunol 9: 353-359.
9. Abraham, E, Anzueto, A, Gutierrez, G, Tessler, S, San Pedro, G, Wunderink, R et al. (1998). Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 351: 929-933.
10. Abraham, E, Laterre, PF, Garbino, J, Pingleton, S, Butler, T, Dugernier, T et al.; Lenercept Study Group. (2001). Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo?controlled, multicenter phase III trial with 1,342 patients. Crit Care Med 29: 503-510.
11. Le Blanc, K, Rasmusson, I, Sundberg, B, G?therstr?m, C, Hassan, M, Uzunel, M et al. (2004). Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363: 1439-1441.
12. Gnecchi, M, He, H, Melo, LG, Noiseaux, N, Morello, F, de Boer, RA et al. (2009). Early beneficial effects of bone marrow-derived mesenchymal stem cells overexpressing Akt on cardiac metabolism after myocardial infarction. Stem Cells 27: 971-979.
13. Lange, C, T?gel, F, Ittrich, H, Clayton, F, Nolte-Ernsting, C, Zander, AR et al. (2005). Administered mesenchymal stem cells enhance recovery from ischemia/reperfusioninduced acute renal failure in rats. Kidney Int 68: 1613-1617. (Pubitemid 43169906)
14. Estrada, EJ, Valacchi, F, Nicora, E, Brieva, S, Esteve, C, Echevarria, L et al. (2008). Combined treatment of intrapancreatic autologous bone marrow stem cells and hyperbaric oxygen in type 2 diabetes mellitus. Cell Transplant 17: 1295-1304.
15. García-Olmo, D, García-Arranz, M, Herreros, D, Pascual, I, Peiro, C and Rodriguez?Montes, JA (2005). A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum 48: 1416-1423.
16. Gonzalez-Rey, E, Anderson, P, González, MA, Rico, L, B'scher, D and Delgado, M (2009). Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut 58: 929-939.
17. González, MA, Gonzalez-Rey, E, Rico, L, B'scher, D and Delgado, M (2009). Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology 136: 978-989.
18. Németh, K, Leelahavanichkul, A, Yuen, PS, Mayer, B, Parmelee, A, Doi, K et al. (2009). Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 15: 42-49.
19. van Poll, D, Parekkadan, B, Cho, CH, Berthiaume, F, Nahmias, Y, Tilles, AW et al. (2008). Mesenchymal stem cell-derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo. Hepatology 47: 1634-1643.
20. Yagi, H, Soto-Gutierrez, A, Kitagawa, Y, Tilles, AW, Tompkins, RG and Yarmush, ML (2010). Bone marrow mesenchymal stromal cells attenuate organ injury induced by LPS and burn. Cell Transplant (epub ahead of print).
21. Liu, SF and Malik, AB (2006). NF-kappa B activation as a pathological mechanism of septic shock and inflammation. Am J Physiol Lung Cell Mol Physiol 290: L622-L645.
22. Wan, Y, Xiao, H, Affolter, J, Kim, TW, Bulek, K, Chaudhuri, S et al. (2009). Interleukin-1 receptor-associated kinase 2 is critical for lipopolysaccharide-mediated posttranscriptional control. J Biol Chem 284: 10367-10375.
23. Hiscott, J, Marois, J, Garoufalis, J, D?Addario, M, Roulston, A, Kwan, I et al. (1993). Characterization of a functional NF-kappa B site in the human interleukin 1 beta promoter: evidence for a positive autoregulatory loop. Mol Cell Biol 13: 6231-6240.
24. Mathurin, P, Deng, QG, Keshavarzian, A, Choudhary, S, Holmes, EW and Tsukamoto, H (2000). Exacerbation of alcoholic liver injury by enteral endotoxin in rats. Hepatology 32: 1008-1017.
25. Frank, S, Zacharowski, K, Wray, GM, Thiemermann, C and Pfeilschifter, J (1999). Identification of copper/zinc superoxide dismutase as a novel nitric oxide-regulated gene in rat glomerular mesangial cells and kidneys of endotoxemic rats. FASEB J 13: 869-882.
26. Fischer, E, Marano, MA, Van Zee, KJ, Rock, CS, Hawes, AS, Thompson, WA et al. (1992). Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest 89: 1551-1557.
27. Parekkadan, B, van Poll, D, Suganuma, K, Carter, EA, Berthiaume, F, Tilles, AW et al. (2007). Mesenchymal stem cell-derived molecules reverse fulminant hepatic failure. PLoS ONE 2: e941.
28. Lama, VN, Smith, L, Badri, L, Flint, A, Andrei, AC, Murray, S et al. (2007). Evidence for tissue-resident mesenchymal stem cells in human adult lung from studies of transplanted allografts. J Clin Invest 117: 989-996.
29. Yao, YM, Redl, H, Bahrami, S and Schlag, G (1998). The inflammatory basis of trauma/shock-associated multiple organ failure. Inflamm Res 47: 201-210.
30. Baue, AE, Durham, R and Faist, E (1998). Systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), multiple organ failure (MOF): are we winning the battle? Shock 10: 79-89.
31. Aggarwal, S and Pittenger, MF (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105: 1815-1822.
32. Hale, KK, Smith, CG, Baker, SL, Vanderslice, RW, Squires, CH, Gleason, TM et al. (1995). Multifunctional regulation of the biological effects of TNF-alpha by the soluble type I and type II TNF receptors. Cytokine 7: 26-38.
33. Diez-Ruiz, A, Tilz, GP, Zangerle, R, Baier-Bitterlich, G, Wachter, H and Fuchs, D (1995). Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur J Haematol 54: 1-8.
34. Lantz, M, Malik, S, Slevin, ML and Olsson, I (1990). Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans. Cytokine 2: 402-406.
35. Wallis, RS (2008). Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 8: 601-611.
36. Leroy, S, Guigonis, V, Bruckner, D, Emal-Aglae, V, Desch?nes, G, Bensman, A et al. (2009). Successful anti-TNFalpha treatment in a child with posttransplant recurrent focal segmental glomerulosclerosis. Am J Transplant 9: 858-861.
37. Cuzzocrea, S, Chatterjee, PK, Mazzon, E, Serraino, I, Dugo, L, Centorrino, T et al. (2002). Effects of calpain inhibitor I on multiple organ failure induced by zymosan in the rat. Crit Care Med 30: 2284-2294.
38. Uccelli, A, Moretta, L and Pistoia, V (2008). Mesenchymal stem cells in health and disease. Nat Rev Immunol 8: 726-736.
39. Aurich, H, Sgodda, M, Kaltwasser, P, Vetter, M, Weise, A, Liehr, T et al. (2009). Hepatocyte differentiation of mesenchymal stem cells from human adipose tissue in vitro promotes hepatic integration in vivo. Gut 58: 570-581.
40. Chan, JL, Tang, KC, Patel, AP, Bonilla, LM, Pierobon, N, Ponzio, NM et al. (2006). Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma. Blood 107: 4817-4824.
41. Di Ianni, M, Del Papa, B, De Ioanni, M, Moretti, L, Bonifacio, E, Cecchini, D et al. (2008). Mesenchymal cells recruit and regulate T regulatory cells. Exp Hematol 36: 309-318.
42. Djouad, F, Charbonnier, LM, Bouffi, C, Louis-Plence, P, Bony, C, Apparailly, F et al. (2007). Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells 25: 2025-2032.
43. Ryan, JM, Barry, F, Murphy, JM and Mahon, BP (2007). Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 149: 353-363.
44. Ryan, JM, Barry, FP, Murphy, JM and Mahon, BP (2005). Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond) 2: 8.
45. Lederer, JA, Rodrick, ML and Mannick, JA (1999). The effects of injury on the adaptive immune response. Shock 11: 153-159.
46. Tomchuck, SL, Zwezdaryk, KJ, Coffelt, SB, Waterman, RS, Danka, ES and Scandurro, AB (2008). Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses. Stem Cells 26: 99-107.
47. Johnson, GB, Brunn, GJ and Platt, JL (2004). Cutting edge: an endogenous pathway to systemic inflammatory response syndrome (SIRS)-like reactions through toll-like receptor 4. J Immunol 172: 20-24.
48. Parekkadan, B, van Poll, D, Megeed, Z, Kobayashi, N, Tilles, AW, Berthiaume, F et al. (2007). Immunomodulation of activated hepatic stellate cells by mesenchymal stem cells. Biochem Biophys Res Commun 363: 247-252.
49. Lin, YZ, Yao, SY, Veach, RA, Torgerson, TR and Hawiger, J (1995). Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem 270: 14255-14258.
50. King, KR, Wang, S, Irimia, D, Jayaraman, A, Toner, M and Yarmush, ML (2007). A high-throughput microfluidic real-time gene expression living cell array. Lab Chip 7: 77-85.